|
業務類別
|
Biotechnology |
|
業務概覽
|
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909. |
| 公司地址
| 99 Coolidge Avenue, Suite 500, Watertown, MA, USA, 02472 |
| 電話號碼
| +1 617 586-3100 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.foghorntx.com |
| 員工數量
| 106 |
| Mr. Jeff Sacher |
Treasurer |
-- |
23/02/2026 |
| Dr. Alfonso Quintas-Cardama, M.D. |
Chief Medical Officer |
美元 494.00K |
30/04/2026 |
| Mr. Carlos Costa |
Chief People Officer |
-- |
30/04/2026 |
| Dr. Steven F. Bellon, PhD |
Chief Scientific Officer |
美元 505.00K |
30/04/2026 |
| Mr. Adrian Gottschalk |
President, Chief Executive Officer and Director |
美元 638.00K |
30/04/2026 |
| Dr. Anna Rivkin, PhD |
Chief Business Officer |
-- |
30/04/2026 |
| Mr. Michael J. LaCascia |
Chief Legal Officer |
-- |
30/04/2026 |
| Mr. Ryan D. Maynard |
Chief Financial Officer and Principal Accounting Officer |
-- |
23/02/2026 |
|
|
| Mr. Ian F. Smith |
Independent Director |
30/04/2026 |
| Mr. Stuart M. Duty |
Independent Director |
30/04/2026 |
| Mr. Adrian Gottschalk |
President, Chief Executive Officer and Director |
30/04/2026 |
| Dr. Michael Mendelsohn, M.D. |
Independent Director |
30/04/2026 |
| Dr. Balkrishan Gill, PhD |
Independent Director |
30/04/2026 |
| Dr. Scott Biller, PhD |
Independent Director |
30/04/2026 |
| Dr. Neil Gallagher, M.D.,PhD |
Independent Director |
30/04/2026 |
| Dr. Thomas J. Lynch, Jr,M.D. |
Independent Director |
30/04/2026 |
| Dr. Douglas G. Cole, M.D. |
Chairman of the Board |
30/04/2026 |
| Ms. B. Lynne Parshall, Esq.,J.D. |
Independent Director |
30/04/2026 |
|
|
|
|
